Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia

NCT03397134 | Completed Phase 3 Results FDA Drug

• 1 other identifier: MIN-101C07
• Study Type: interventional
• Target: 515
• Locations: 4 countries
• Sites: 39

Brief Summary

MIN-101C07 is a multicenter, multinational, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of roluperidone in adult schizophrenia patients.The primary objective is to evaluate the efficacy of 2 fixed doses of roluperidone compared to placebo in improving the negative symptoms of schizophrenia over 12 weeks of double-blind treatment as measured by the change in Positive and Negative Syndrome Scale (PANSS) Marder negative symptoms factor score (NSFS) over 12 weeks.

Conditions

Negative Symptoms of Schizophrenia

Outcome Measures

Primary Outcomes (1)

• Change From Baseline to Week 12 in PANSS Marder Negative Symptoms Factor Score (NSFS)

  The Marder negative symptoms factor score (NSFS) derived from the complete Positive and Negative Syndrome Scale (PANSS) has been the most frequently used scale in schizophrenia clinical studies focusing on negative symptoms The PANSS measures comprehensive psychiatric symptoms, including positive, negative, and general symptoms. The full PANSS rates the patient on 30 different symptoms from 1 (absent) to 7 (extreme) based on an interview as well as reports of family members or primary care hospital workers. The NSFS consists of the sum of the negative symptom PANSS items N1, N2, N3, N4, N6, G7, and G16 (minimum score = 7; maximum score = 49). Higher scores indicate more severe symptoms.

  Baseline, Week 2, Week 4, Week 8, and Week 12

Secondary Outcomes (9)

• Change From Baseline to Week 12 in Personal and Social Performance (PSP)

  Baseline, Week 4, Week 8, and Week 12

• Change From Baseline to Week 12 in Clinical Global Impression of Severity (CGI-S)

  Baseline, Week 2, Week 4, Week 8, and Week 12

• Number of Participants With Potentially Clinically Significant Laboratory Values (Whole Study Period; Safety Population)

  Entire study (which includes double-blind and open-label periods) from Baseline to Week 54 (referred to as the "whole study period")

• Number of Participants With Potentially Clinically Significant ECG Parameters (Whole Study Period; Safety Population)

  Entire study (which includes double-blind and open-label periods) from Baseline to Week 54 (referred to as the "whole study period")

• Number of Participants With Potentially Clinically Significant Vital Signs (Whole Study Period; Safety Population)

  Entire study (which includes double-blind and open-label periods) from Baseline to Week 54 (referred to as the "whole study period")

Study Arms (4)

Roluperidone 64 mg

EXPERIMENTAL

Roluperidone 64 mg for entire study

Drug: Roluperidone 64 mg

Roluperidone 32 mg

EXPERIMENTAL

Roluperidone mg for entire study

Drug: Roluperidone 32 mg

Placebo-1

PLACEBO COMPARATOR

Placebo for 12 weeks followed by Roluperidone 64 mg during open-label extension

Drug: Placebo Oral Tablet; Drug: Roluperidone 64 mg

Placebo-2

PLACEBO COMPARATOR

Placebo for 12 weeks followed by Roluperidone 32 mg during open-label extension

Drug: Placebo Oral Tablet; Drug: Roluperidone 32 mg

Interventions

Placebo Oral Tablet DRUG

Placebo administered as a single dose once daily

Placebo-1; Placebo-2

Roluperidone 32 mg DRUG

Roluperidone administered as a single dose once daily

Placebo-2; Roluperidone 32 mg

Roluperidone 64 mg DRUG

Roluperidone administered as a single dose once daily

Placebo-1; Roluperidone 64 mg

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Patient and patient's legal representative, if applicable, provided informed consent prior to the initiation of any study related procedures, and the patient is judged by the investigator as being capable of understanding the study requirements.
• Male or female patient, 18 to 55 years of age, inclusive, and body mass index (BMI) \< 35 kg/m(2) at Screening.
• Patient meets the diagnostic criteria for schizophrenia as defined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), as established by a full psychiatric interview in conjunction with the Mini International Neuropsychiatric Interview.
• Has a reliable caregiver or family member or health care personnel who can provide information towards assessment and support the patient in terms of compliance with the protocol. The caregiver must have contacts with the patient daily for at least 1 hour each time and is not expected to change during the trial.
• Documented diagnosis of schizophrenia for at least 1 year before screening into the trial.
• Patient is stable in terms of positive and negative symptoms of schizophrenia over the last 6 months according to his or her treating psychiatrist and based on documentation in the clinical chart.
• Patient is currently an outpatient and has not been hospitalized for the last 6 months for acute exacerbation or symptoms worsening. Patients hospitalized during the last 6 months for social reasons or are currently hospitalized for social reasons can be included only with Sponsor's Responsible Medical Officer's approval, and the social reasons must be documented in the electronic case report form (eCRF).
• Patient with a score of \> 20 on the PANSS negative subscore (the original PANSS scale \[ Sum of N1+N2+N3+N4+N5+N6+N7\]) at Screening (Visit 1) and Baseline (Visit 3) AND \< 4 points absolute difference between 2 visits.
• Patients can be on any psychotropic before the trial if the psychotropics can be discontinued at the beginning of the washout phase without risking the patient's clinical status or safety.
• No history of violence against self or others during the last 1 year.
• Female patient who are not of childbearing potential, defined as women who are postmenopausal (defined as spontaneous amenorrhoea for at least 1 year or spontaneous amenorrhoea for at least 6 months confirmed by follicle stimulating hormone result of ≥ 40 IU/mL) or permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy).
• Female patient, if of childbearing potential, must test negative for pregnancy and must be using a double barrier contraceptive method.
• Patient must be extensive metabolizers for cytochrome P450 (CYP2D6), defined as a subject that has at least one functional allel (e.g., \*1 or \*2), as determined by study-specific genotyping test before the first drug dose is administered.
• Patient and the caregiver are considered by the investigator to be reliable and likely to cooperate with the assessment procedures.

You may not qualify if:

• Current major depressive disorder, bipolar disorder, panic disorder, obsessive compulsive disorder, or intellectual disability (intellectual developmental disorder diagnosed by age 14).
• Patient with PANSS item score of \> 4 on: P4 excitement/hyperactivity, P6 suspiciousness/persecution, P7 hostility, G8 uncooperativeness, G14 poor impulse control.
• A Calgary Depression Scale for Schizophrenia (CDSS) total score \> 6.
• A score of ≥ 2 on any 2 items 1, 2, or 3, or a score of ≥ 3 on item 4 of the Barnes Akathisia Rating Scale (BARS).
• Patient's condition is due to direct psychological effects of a substance (e.g., a drug of abuse, or medication) or a general medical condition.
• Has a current or recent history of serious suicidal behavior within the past 1 year.
• Patient has a history of substance use disorder within 3 months of the Screening visit (excluding caffeine and cigarette smoking).
• Positive urine drug screen for drugs of abuse (cocaine, methadone, amphetamines, cannabinoids, opiates, benzodiazepines, and barbiturates), tricyclic antidepressants (TCA), and alcohol (except for prescription benzodiazepines).
• Patient who cannot be discontinued from psychotropics other than those allowed.
• Patient who received clozapine within 6 months of the Screening visit.
• Patient receiving treatment with long-acting or depot antipsychotic medication unless his/her next scheduled dose will occur during the protocol Screening period and can be omitted to allow for sufficient washout before receiving the study drug.
• Patient with a history of significant other major or unstable neurological, neurosurgical (e.g., head trauma), metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, or urological disorder.
• Patient with a history of seizures (patient with a history of a single childhood febrile seizure may be enrolled in this study).
• Patient who has had electroconvulsive therapy (ECT), vagal nerve stimulation (VNS), or repetitive trans-cranial magnetic stimulation (r-TMS) within the 6 months prior to the Screening visit or who are scheduled for ECT, VNS, or r-TMS at any time during the study.
• Patient with clinically significant abnormalities in hematology, blood chemistry, ECG, or physical examination not resolved by the Baseline visit which according to Investigator can interfere with study participation.

Sponsors & Collaborators

• Minerva Neurosciences: lead

Study Sites (39)

Woodland Research Northwest

Rogers, Arkansas, 72758, United States

Location

ProScience Research Group

Culver City, California, 90230, United States

Location

Collaborative Neuroscience Network, LLC.

Garden Grove, California, 92845, United States

Location

Synergy Clinical Center

National City, California, 91950, United States

Location

Collaborative Neuroscience Network, LLC.

Torrance, California, 90502, United States

Location

Behavioral Clinical Research, Inc

North Miami, Florida, 33161, United States

Location

Research Centers of America, LLC

Oakland Park, Florida, 33334, United States

Location

Atlanta Center for Medical Research

Atlanta, Georgia, 30331, United States

Location

Uptown Research Institute LLC

Chicago, Illinois, 60640, United States

Location

Hassman Research Institute, LLC.

Berlin, New Jersey, 08009, United States

Location

The Nathan Kline Institute for Psychiatric Research

Orangeburg, New York, 10962, United States

Location

InSite Clinical Research LLC

DeSoto, Texas, 75115, United States

Location

Pillar Clinical Research LLC

Richardson, Texas, 75080, United States

Location

"State Psychiatric Hospital - Tserova Koria"; Department for Active Treatment of Severe Psychosis - male; Department for Active Treatment of Severe Psychosis - male

Tserova Koria, Veliko Tarnovo District, Bulgaria

Location

"Mental Health Center Prof. Dr. Ivan Temkov - Burgas" EOOD Department For Treatment of Emergency Psychiatry Conditions

Burgas, Bulgaria

Location

State Psychiatry Hospital - Lovech

Lovech, Bulgaria

Location

State Psychiatry Hospital "Sveti Ivan Rilski" Department of General Psychiatry for adults "closed type" - males; Department of General Psychiatry for adults "closed type" - females

Novi Iskar, Bulgaria

Location

'Mental Health Center Plovdiv"-EOOD Department for treatment of acute female/male psychoses with endogenous, exogenous, organic psychotic disturbances of the personality

Plovdiv, Bulgaria

Location

Multiprofile Hospital for Active Treatment - Targovishte" AD Department of Psychiatry

Targovishte, Bulgaria

Location

"Mental Health Center - Vratsa" General Psychiatric Department

Vratsa, Bulgaria

Location

Samodzielny Publiczny Psychiatryczny zakład opieki zdrowotnej im Dr. Stanisława Deresza w Choroszczy

Choroszcz, Poland

Location

Medical University of Gdańsk, Department of Psychiatry UCK

Gdansk, Poland

Location

Klinika Psychiatryczna Inventiva

Tuszyn, Poland

Location

Communal Institution "Dnipropetrovsk Regional Clinical Hospital n.a. I.I. Mechnikov," Regional Centre for Psychosomatic Disorders based on Psychoneurological Department

Dnipro, Ukraine

Location

Ivano-Frankivsk National Medical University (IFNMU) - Regional Psycho-Neurological Hospital #3

Ivano-Frankivsk, Ukraine

Location

Kharkiv Railway Clinical Hospital N°1 of Branche "Health Center" of the Public joint stock company "Ukrainian Railway," Psychiatry Department

Kharkiv, Ukraine

Location

State Institution "Institute of Neurology, Psychiatry and Narcology of National Academy of Medical Science of Ukraine," Department of Emergency Psychiatry and Narcology

Kharkiv, Ukraine

Location

State Institution "Institute of Neurology, Psychiatry and Narcology of National Academy of Medical Science of Ukraine," Department of Neuroses and Borderline Conditions

Kharkiv, Ukraine

Location

State Institution "Institute of Neurology, Psychiatry and Narcology of National Academy of Medical Sciences of Ukraine," Department of Clinical, Social and Child Psychiatry

Kharkiv, Ukraine

Location

Kyiv Regional Medical Incorporation "Psychiatry," Centre of Novel Treatment and Rehabilitation of Psychotic Disorders based on Department #29 and Department #30

Kyiv, Ukraine

Location

Communal Institution of Lviv Regional Council "Lviv Regional Clinical Psychiatric Hospital," Department #20

Lviv, Ukraine

Location

Communal Institution of Lviv Regional Council "Lviv Regional Clinical Psychiatry Hospital," General Psychiatric Mixed Department #25

Lviv, Ukraine

Location

Odessa Regional Medical Centre of Mental Health, Dept. #6 (male), Dept. #12 (female)

Odesa, Ukraine

Location

Kyiv Regional Medical Incorporation "Psychiatry," Centre of Novel Treatment and Rehabilitation of Psychotic Disorders based on Department #29 and Department #30

Oleksandrivka, Ukraine

Location

"Ukrainian medical stomatological academy," Chair of psychiatry, narcology and medical psychology based on Poltava Regional Clinical Psychiatric Hospital named after O.F. Maltsev, female acute general psych. dept. 5-b, male acute general psych. dept 2-a

Poltava, Ukraine

Location

Communal Institution "Cherkasy Regional Psychiatric Hospital"

Smila, Ukraine

Location

Municipal Institution Kherson Regional Psychiatric Hospital of Regional Council

Stepanovka, Ukraine

Location

Ternopil Regional Municipal Clinical Psychoneurological Hospital

Ternopil, Ukraine

Location

Municipal Institution "Vinnytsya Regional Psychoneurological Hospital n.a. Acad. O.I. Yushchenko," Male Department No 14, Female Department No 15

Vinnytsia, Ukraine

Location

Related Publications (1)

• Davidson M, Saoud J, Staner C, Noel N, Werner S, Luthringer E, Walling D, Weiser M, Harvey PD, Strauss GP, Luthringer R. Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia. Schizophr Bull. 2022 May 7;48(3):609-619. doi: 10.1093/schbul/sbac013.

  PMID: 35211743 RESULT

MeSH Terms

Interventions

roluperidone

Results Point of Contact

• Title: Senior Vice President and Head of R&D
• Organization: Minerva Neurosciences

rkuchibhatla@minervaneurosciences.com

617-600-7378

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 29, 2017
• First Posted: January 11, 2018
• Study Start: December 15, 2017
• Primary Completion: May 26, 2020
• Study Completion: February 15, 2021
• Last Updated: April 28, 2023
• Results First Posted: April 28, 2023

Record last verified: 2023-04

Locations

PL (3); US (13); UA (16); BU (7)